Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
Roughly one third of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-sensitive mutated (EGFRm) tumors experience disease progression through central nervous system (CNS) metastases during treatment. Although EGFR-TKIs have been r...
Saved in:
Main Authors: | Yuhan Zhang (Author), Yaoshuai Zhang (Author), Wenwen Niu (Author), Xianming Ge (Author), Fuhao Huang (Author), Jinlong Pang (Author), Xian Li (Author), Yu Wang (Author), Wei Gao (Author), Fangtian Fan (Author), Shanshan Li (Author), Hao Liu (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Restricting Glutamine Uptake Enhances NSCLC Sensitivity to Third-Generation EGFR-TKI Almonertinib
by: Yaming Liu, et al.
Published: (2021) -
Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
by: Xiaoying Hou, et al.
Published: (2018) -
Case Report: Response to Almonertinib in a Patient With Metastatic NSCLC Resistant to Osimertinib due to Acquired EGFR L718Q Mutation
by: Gang Shen, et al.
Published: (2021) -
The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022) -
Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)